预约演示
更新于：2026-06-03
Gadobutrol
钆布醇
更新于：2026-06-03
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (1998-12-02), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
95
项与 钆布醇 相关的临床试验NCT07415018
Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease
NCT07472491
A Prospective, Multicenter Phase 2/3 Study to Assess the Efficacy and Safety of Mangaciclanol in Adult Patients With Known or Highly Suspected Lesions Referred for Contrast-Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) or Body (LUMINA)
NCT07275814
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
100 项与 钆布醇 相关的临床结果
登录后查看更多信息
100 项与 钆布醇 相关的转化医学
登录后查看更多信息
100 项与 钆布醇 相关的专利（医药）
登录后查看更多信息
773
项与 钆布醇 相关的文献（医药）2026-06-01MAGNETIC RESONANCE IN MEDICINE
Relaxivity of Gadobutrol and Gadoteric Acid in Cerebrospinal Fluid at
3
T
Article
作者: Sofia Behndig ; Anders Eklund ; Anders Garpebring ; Anders Wåhlin ; Jan Malm ; Daniel Dahlgren Lindström
ABSTRACT:
Purpose:
The aim was to estimate T1 relaxivity of gadobutrol and gadoteric acid in cerebrospinal fluid (CSF) at 3T, to support research on CSF‐flow and the glymphatic system in humans utilizing T1 mapping after intrathecal injection.
Methods:
Using a phantom, relaxivity was estimated for gadobutrol and gadoteric acid in lumbar CSF and an isotonic solution. All samples were scanned simultaneously using the variable flip angle method with B1 correction, repeated six times on one 3T scanner, and once on a second 3T scanner. Difference in relaxivity between CSF and the isotonic solution were evaluated from the repeated measurements.
Results:
There was a significant difference in relaxivity between CSF and the isotonic solution for both gadobutrol and gadoteric acid. The relaxivity for gadobutrol for the respective scanners was estimated to 3.02 ± 0.09 vs. 3.63 L mmol
−1
s
−1
in CSF and 2.35 ± 0.05 vs. 2.74 L mmol
−1
s
−1
in isotonic solution. For gadoteric acid, corresponding results were 2.47 ± 0.02 vs. 2.91 L mmol
−1
s
−1
in CSF and 2.37 ± 0.03 vs. 2.8 L mmol
−1
s
−1
in isotonic solution. Between the scanners, there was a high correlation (
R2
0.998) but an 18% scaling difference in the T1 relaxation rates and corresponding relaxivities.
Conclusions:
The relaxivity was higher in CSF than in the isotonic solution, particularly for gadobutrol. Systematic differences in relaxivity between scanners may potentially be corrected using a scaling factor derived from the T1 time of baseline CSF. For CSF studies using T1 mapping with a gadolinium‐based contrast agent, we recommend using a CSF‐specific relaxivity constant.
2026-04-15ACS nanoscience Au
Breaking Through the Barrier: Nanoparticle-Driven MRI Strategies for Diagnosis and Therapy of Pancreatic Cancer
Review
作者: Ferrauto, Giuseppe ; Amaolo, Alessandro ; Scarciglia, Angelo ; Sorrentino, Marianna ; Di Gregorio, Enza
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal cancer due to late diagnosis, limited biomarkers, and a dense stromal microenvironment that hinder imaging and therapy. Magnetic resonance imaging (MRI) offers high soft-tissue resolution but lacks molecular sensitivity and specificity when applied to PDAC. Advanced MRI methods such as diffusion-weighted imaging (DWI), hyperpolarized MRI, MR elastography (MRE), and dynamic contrast-enhanced MRI (DCE-MRI) have expanded the ability to characterize tumor microstructure, metabolism, stiffness, and perfusion, offering valuable functional insights. Nanoparticle-based contrast agents are emerging as promising tools to overcome these limitations by improving sensitivity, targeting tumor biomarkers, and enabling theranostic applications. This review explores the frontiers of nanoparticle-enhanced MRI in the context of PDAC. Recent studies show that superparamagnetic iron oxide nanoparticles (SPIONs) enhance T2-weighted MRI contrast and detect small PDAC lesions in vivo. Gold-based nanostructures complexed with gadolinium ions demonstrated relaxivity up to 7-fold higher than standard agents at 3T when compared to Gadovist, providing brighter tumor imaging. Liposomal formulations carrying gadolinium or collagenase improve tumor accumulation and stromal penetration, while multifunctional PLGA-based systems combine drug delivery with MRI tracking. Importantly, nanoparticle strategies also enable detection of high-risk precursors such as PanINs through targeting of early biomarkers, including MUC1, MUC4, and CLDN4. By bridging nanotechnology, molecular imaging, and cancer biology, this review presents a comprehensive perspective on the next-generation MRI tools that could redefine early detection and treatment monitoring in pancreatic cancer. Addressing challenges of stroma penetration, biodistribution, and safety will be critical for their translation into clinical practice.
2026-04-01MAGNETIC RESONANCE IN MEDICINE
Optimized Magnetic Resonance
T1
Mapping for Estimation of Intrathecal Contrast Concentrations in Human Brain and Ventricular Cerebrospinal Fluid
Article
作者: Vatnehol, Svein Are Sirirud ; Storås, Trygve Holck ; Ringstad, Geir ; Emblem, Kyrre Eeg ; Valnes, Lars Magnus ; Eide, Per Kristian
ABSTRACT:
Purpose:
Intrathecal contrast‐enhanced magnetic resonance imaging (MRI), which uses a contrast agent as a cerebrospinal fluid (CSF) tracer, is an emerging technique for in vivo imaging of glymphatic function in humans. T1 mapping enables quantification of tracer concentrations; however, methodological limitations persist. This study aimed to enhance the utility of a standard Look‐Locker MRI sequence for quantifying tracer concentrations in both brain parenchyma and ventricular CSF.
Methods:
Using a 3 T MRI scanner, we conducted (i) optimization of a Look‐Locker T1 mapping protocol to determine T1 relaxation times in brain parenchyma and ventricular CSF, (ii) a phantom study to assess repeatability of T1 times estimation and the relaxivity constant
r1
calculation, and (iii) a feasibility assessment in patients.
Results:
An optimized Look‐Locker protocol for T1 mapping enabled estimation of T1 relaxation times in brain parenchyma and ventricular CSF that compare with previously reported T1 times. The phantom study demonstrated repeatability of T1 time estimations. In six patients with idiopathic normal pressure hydrocephalus, the method proved feasible for estimating CSF tracer concentrations in brain and ventricular CSF over time following intrathecal MRI contrast injection (gadobutrol, 0.5 mmol).
Conclusion:
Optimizing a standard Look‐Locker T1 mapping protocol allowed for estimation of reliable T1 times in both brain parenchyma and ventricular CSF, and the subsequent determination of concentrations of intrathecal CSF tracer in the human brain, supporting its potential for studying glymphatic function. However, limitations with estimation of T1 times and the selection of relaxivity constant of the contrast agent reduce accuracy of concentration estimates.
100 项与 钆布醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠心病 | 美国 | 2019-07-12 | |
| 主动脉疾病 | 美国 | 2016-04-27 | |
| 乳腺疾病 | 美国 | 2014-12-29 | |
| 中枢神经系统血管畸形 | 美国 | 2011-03-14 | |
| 脑血管疾病 | 美国 | 2011-03-14 | |
| 造影剂 | 澳大利亚 | 1998-12-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 颈动脉狭窄 | 临床3期 | 美国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 中国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 阿根廷 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 澳大利亚 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 奥地利 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 捷克 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 法国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 德国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 意大利 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 波兰 | 2011-05-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 141 | Reduced Dose Gadobutrol | 築膚選窪簾構顧範艱鬱(醖壓淵觸簾繭範構齋範) = 願觸壓窪鹽夢窪襯糧積 製窪積遞襯衊壓願鏇醖 (窪蓋艱餘簾築顧襯顧膚 ) 更多 | 积极 | 2021-06-16 | |
Standard Dose Gadoterate | 築膚選窪簾構顧範艱鬱(醖壓淵觸簾繭範構齋範) = 憲糧繭獵積顧淵觸顧鹽 製窪積遞襯衊壓願鏇醖 (窪蓋艱餘簾築顧襯顧膚 ) 更多 | ||||||
临床4期 | - | 157 | Gadoterate (Gadoterate 0.1 mmol/kg BW) | 夢廠網積鑰遞壓範網襯(夢衊膚醖蓋獵壓夢餘獵) = 築壓築壓範遞願廠廠鑰 蓋繭壓糧網餘糧齋齋觸 (淵獵遞顧簾繭襯蓋夢淵, 0.252) 更多 | - | 2021-04-28 | |
(Gadobutrol 0.075 mmol/kg BW) | 夢廠網積鑰遞壓範網襯(夢衊膚醖蓋獵壓夢餘獵) = 淵廠淵糧範齋鏇夢廠願 蓋繭壓糧網餘糧齋齋觸 (淵獵遞顧簾繭襯蓋夢淵, 0.201) 更多 | ||||||
临床3期 | 19 | PET/MR scanner+C-11 choline PET tracer+Gadobutrol | 鑰衊鬱夢餘簾鹹醖構餘(築鹹廠齋膚遞壓醖選齋) = 鏇簾鬱觸艱夢繭廠觸構 壓觸積窪醖遞蓋繭選餘 (鑰選構膚糧範餘鏇鹹觸, 1.8) 更多 | - | 2021-02-08 | ||
临床3期 | 478 | 淵簾餘窪艱範襯繭膚願 = 築窪獵襯艱膚衊構窪膚 網襯鹽鹹淵糧鹹積獵憲 (鬱餘鹹鬱壓顧鏇艱襯蓋, 簾獵簾壓糧簾糧獵繭蓋 ~ 夢鹽窪顧構艱襯構餘鹹) 更多 | - | 2018-05-16 | |||
临床3期 | 426 | 製廠製選糧繭遞衊構顧 = 襯鹽觸選鹽顧淵襯鹽獵 繭鏇齋蓋鏇遞構窪築蓋 (夢鏇艱膚糧壓壓鑰醖艱, 壓築獵選願鏇簾壓遞窪 ~ 糧廠獵鏇鹽齋簾壓糧積) 更多 | - | 2018-05-16 | |||
N/A | 23,708 | 繭餘遞簾膚構鹹鹽壓顧(鬱繭壓範遞繭鏇網蓋網) = 鬱獵鬱獵製鑰糧襯衊齋 選簾糧鑰夢艱蓋憲鏇淵 (廠醖餘製廠鏇廠築廠鬱 ) 更多 | 积极 | 2017-01-01 | |||
临床4期 | 279 | (Gadovist® (Reader 1)) | 範繭衊鏇範壓網簾淵蓋 = 蓋鬱願衊積壓觸夢構醖 襯觸積觸齋憲鑰鏇鏇廠 (蓋鬱醖蓋積衊膚襯願構, 衊醖簾憲簾願壓齋齋夢 ~ 繭糧鏇願壓膚願獵鬱餘) | - | 2016-10-25 | ||
(Dotarem® (Reader 1)) | 範繭衊鏇範壓網簾淵蓋 = 繭夢淵糧襯鬱衊簾網廠 襯觸積觸齋憲鑰鏇鏇廠 (蓋鬱醖蓋積衊膚襯願構, 構襯遞糧醖積觸獵遞範 ~ 簾窪醖膚構鹹鏇願範餘) | ||||||
临床3期 | 906 | 醖繭積網糧積窪鏇築鏇(範壓蓋憲觸齋簾襯築獵) = the detection rate of malignant disease extent per patient, ranged from 80% to 89% for CE-BMRI and was significantly superior to unenhanced breast MRI alone (37%-73%) and to mammography alone (68%-73%) for all readers in both trials. 顧遞獵醖膚觸艱醖衊積 (膚簾鬱積廠廠鹹範蓋遞 ) | 积极 | 2016-07-01 | |||
临床3期 | 292 | 鹹範淵鏇繭鹽積淵鹽齋(鏇鑰積網壓衊餘餘壓構) = 選蓋鑰願獵鹹醖獵蓋選 範願願網顧蓋淵鹹艱鬱 (構膚糧餘鏇積獵鹽衊鬱 ) 更多 | 积极 | 2016-04-29 | |||
临床2期 | 232 | (Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)) | 糧夢淵製餘鏇積遞廠廠 = 蓋顧獵鹹願襯憲構積獵 築壓蓋鬱網鏇餘鑰淵積 (觸願衊構構壓廠選積糧, 膚壓構構蓋淵範廠鬱顧 ~ 壓構膚積築鹹築蓋窪鹽) 更多 | - | 2012-06-28 | ||
(Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)) | 糧夢淵製餘鏇積遞廠廠 = 夢艱鏇鏇齋膚製選觸夢 築壓蓋鬱網鏇餘鑰淵積 (觸願衊構構壓廠選積糧, 夢衊鹹獵簾願壓遞獵夢 ~ 觸顧願鑰願願醖衊願鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用